Trials / Completed
CompletedNCT03154892
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Detailed description
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Intracameral injection | Intracameral Conbercept injection for the treatment of NVG |
| PROCEDURE | Intravitreal injection | Intravitreal Conbercept injection for the treatment of NVG |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2017-05-16
- Last updated
- 2018-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03154892. Inclusion in this directory is not an endorsement.